Endothelial Progenitor Cells in Neurovascular Disorders: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Ewa Rudnicka-Drożak
,
Paulina Drożak
,
Grzegorz Mizerski
,
Martyna Drożak

Endothelial progenitor cells (EPCs) are a population of cells that circulate in the blood looking for areas of endothelial or vascular injury in order to repair them. Endothelial dysfunction is an important component of disorders with neurovascular involvement. EPCs have a capacity to repair or replace the damaged endothelium through a differentiation into mature endothelial cells, which are able to embed into the new vessels. Moreover, through a secretion of various growth factors, including stromal cell-derived factor-1α (SDF-1α), vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF-1), they promote angiogenesis or vasculogenesis and recruit more EPCs. EPCs express various cell markers on their surface, which include both markers characteristic for hematopoietic stem cells (CD34 and CD133) and markers characteristic for endothelial cells, such as VEGFR-2 (vascular endothelial growth factor receptor-2), vWF (von Willebrand factor), VE-cadherin (vascular endothelial cadherin) or CD144, Tie-2, CD62E (e-selectin) and c-kit/CD117.

  • endothelial progenitor cells
  • endothelial dysfunction
  • Alzheimer disease
  • ischemic stroke

1. Alzheimer’s Disease

Studies have demonstrated that previously occurring vascular and endothelial dysfunction lead to the development of Alzheimer’s disease (AD). Comorbid cerebrovascular disease often accompanies AD. It is believed to have an additive effect on cognitive impairment and lower the threshold for dementia [1]. A dysfunction of cerebral vasculature is one of the earliest occurring events in the pathogenesis of AD [2][3]. According to the two-hit hypothesis of AD, first proposed by Zlokovic, vascular pathology appears primary and contributes to Alzheimer’s tau pathology. Vascular risk factors, such as hypertension, diabetes, cardiac disease and/or stroke (hit one) lead to an endothelial dysfunction in the blood–brain barrier (BBB) and a reduction in cerebral blood flow (CBF), which causes oligemia. An endothelial dysfunction of BBB impairs the clearance of amyloid beta (Aβ), whereas oligemia increases production of Aβ, and both processes lead to Aβ accumulation in the brain (hit two). Moreover, endothelial dysfunction within the BBB causes an infiltration of multiple neurotoxic molecules to the brain [4].

2. Cerebral Small Vessel Disease

Endothelial dysfunction has been recognized as the first event that occurs during the pathogenesis of cerebral small vessel disease (CSVD), a primary cause of vascular dementia (VD) [5][6]. Dysfunctional endothelial cells lead to changes in the surrounding cerebral white matter through a secretion of heat shock protein 90α, which hinders oligodendroglial differentiation and, thus, impairs the process of myelination [6]. Moreover, endothelial dysfunction is also related to the impairment of the BBB and a decrease in CBF, and both of these processes are involved in the development of CSVD. An increased permeability of the BBB causes local microhemorrhages and decreases distal blood flow, which leads to an aggravation of the regional ischemia in the brain [7].
Several studies have investigated EPC counts in human individuals with CSVD. Results of the research are conflicting in this regard. Early studies demonstrated that CSVD patients had lower levels of circulating EPCs and decreased EPC cluster counts compared to healthy individuals [8][9]. Later studies differentiated patients according to the burden of CSVD and a very recent study divided EPCs into subpopulations according to their surface markers. Overall, elevated levels of EPCs were related to greater CSVD burden [10][11]. However, circulating CD34+ cells were found to be decreased in the above-mentioned group of patients [11]. These findings suggest that EPC levels may serve as potential biomarkers to track the progression of CSVD.

3. Ischemic Stroke

Endothelial damage, induced by risk factors, such as hypertension, diabetes and hyperlipidemia, is an important event in the pathophysiology of ischemic stroke (IS) [12]. Endothelial dysfunction plays a key role in the onset of stroke through a promotion of atherosclerosis, thrombosis, a disruption of the BBB, oxidative stress, inflammation and increased vascular tone [13]. Patients undergoing an acute ischemic stroke were found to have a severe endothelial dysfunction during the first 24 h of the event [14]. Moreover, endothelial dysfunction also appears as a consequence of IS. Global ischemia, with or without reperfusion, was found to impair endothelium-dependent vascular tone regulation, whereas focal ischemia impairs endothelium-dependent vasodilatation [15].
EPC levels are decreased, overall, in multiple states that elevate the risk of stroke, such as atherosclerosis or hypertension [16][17]. However, the number of early EPCs (CD133+/VEGFR2+) increases during the acute phase of ischemic stroke, together with angiogenic growth factors VEGF and FGF (fibroblast growth factor). However, EPCs and angiogenic growth factor levels were found to be inversely correlated with inflammatory factors, suggesting an unfavorable impact of inflammation on the survival and differentiation of EPCs [18]. One study indicated that the level of circulating EPCs transiently elevates for some time after an acute stroke; first, it gradually increases up to 1 week after stroke onset, then remains elevated at 2 weeks and returns to baseline at day 28 [19]. An increase in SDF-1α was also noted early after the occurrence of IS [20]. A recent study demonstrated that the EPC level in stroke patients is higher in the 3rd and 12th month post-stroke than within 7 days after stroke. The peak in the EPC count was observed at 12 months after an ischemic event and was significantly higher than in healthy controls. However, EPCs from stroke patients showed impaired functionality measured by tube-formation capability compared to EPCs from healthy individuals [21]. A novel in vitro study demonstrated that the secretome of EPCs derived from stroke patients was found to promote angiogenesis and maturation of new vessels together with restoring the function of the BBB in ischemic conditions [22]. It was also found that the EPC level is inversely correlated with severity of ischemic lesion [23]. Moreover, a higher level of CFU-ECs during the first week after IS predicted better functional outcome and was associated with reduced infarct growth [24], whereas a low level of circulating EPCs measured 48 h after IS predicted severe neurological impairment [25]. Migratory and angiogenic capacities of EPCs were also found to be associated with increased collateral flow during the acute phase of the stroke and increased CBF at day 7 post-stroke. On the other hand, no associations were found between EPCs and hemorrhagic transformation or recanalization [13]. Currently, there is one ongoing clinical trial (NCT02980354) that aims to investigate whether the number and functionalities of circulating EPCs could serve as biomarkers of severity and type (cortical/lacunar) of ischemic stroke [26]. In vitro research has demonstrated that OECs migrate to the place of vascular injury and repair it in order to maintain neurovascular homeostasis at a time of or after an ischemic injury in the brain. OECs were observed to establish an equally tight in vitro model of the BBB as brain microvascular endothelial cells (BMECs), which shows their capacity to form tight junctions. Moreover, OECs were found to have a greater proliferative and migratory capacity than BMECs. An exogenous addition of OECs to an in vitro model of the BBB (established with astrocytes, pericytes and BMECs) repaired the wound scratch-induced on a layer of BMECs in serum-free conditions [27]. Additionally, a very recent study demonstrated that an outgrowth endothelial cell-derived conditioned media (OEC-CM) prevents the damaging effects of TNF-α on the BBB since the levels of TNF-α were found to be significantly elevated on days 2, 7, 30 and 90 after ischemic stroke and TNF-α impairs function and integrity of the BBB, which is the main early cause of death after IS [28].

4. Migraine

Endothelial dysfunction is also known to be involved in the pathophysiology of migraine. Oxidative stress and inflammation were identified as two main causes of endothelial damage in migraine. Oxidative stress causes a reduction in the amount of nitric oxide (NO), which leads to vasoconstriction. Moreover, NO insufficiency is associated with perception of pain since NO reduces pain by increasing the cyclic guanosine monophosphate (cGMP) level. Moreover, oxidative stress promotes hypercoagulability. As a consequence, endothelial dysfunction leads to increased vascular tone, inflammation and thrombosis, all of which contribute to migraine [29]. Moreover, studies suggest that migraine, particularly migraine with aura, increases the risk of ischemic stroke [30].
Studies have demonstrated that a lower circulating EPC count is observed in migraineurs. A study by Lee et al. indicated that migraine patients (with or without aura) had a reduced number of EPCs compared to healthy controls and patients with tension type headache (TTH). Moreover, patients with migraine with aura showed lower EPC counts than patients with aura-free migraine. Additionally, EPCs isolated from migraineurs showed reduced migration ability and increased cellular senescence compared to EPCs from normal or TTH subjects [31]. A later study by Rodríguez-Osorio et al. confirmed a lower EPC count in migraine patients and, furthermore, indicated that a number of EPCs decreases with time as migraine progresses [32]. Moreover, one study demonstrated that women suffering from migraine with aura exhibited decreased (compared to age-matched healthy women) SDF-1α, which promotes mobilization of the EPCs from the bone marrow. These results suggest that the compensatory up-regulation of SDF-1α as a response to an injury in migraineurs is somehow disrupted, which adds to the evidence for endothelial dysfunction in migraine [33]. Furthermore, among participants of this study, an inverse correlation was found between the level of SDF-1α and CD144+ and activated CD62E+ endothelial microparticles (EMPs), which are markers of endothelial dysfunction [33][34]. Another study showed that female migraineurs with aura have an increased level of EMPs [35]. Furthermore, another study by Oterino et al. observed a higher number of CD62E+EPCs, a marker of endothelial activation, in migraine patients, both with and without aura [36]. A reduction in and a dysfunction of EPCs in migraine patients was suggested as a link between migraine and cardiovascular risk [31][36].

This entry is adapted from the peer-reviewed paper 10.3390/biomedicines10102616

References

  1. Toledo, J.B.; Arnold, S.E.; Raible, K.; Brettschneider, J.; Xie, S.X.; Grossman, M.; Monsell, S.E.; Kukull, W.A.; Trojanowski, J.Q. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre. Brain 2013, 136 Pt 9, 2697–2706.
  2. Parodi-Rullán, R.; Sone, J.Y.; Fossati, S. Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer’s Disease. J. Alzheimers. Dis. 2019, 72, 1019–1039.
  3. Corriveau, R.A.; Bosetti, F.; Emr, M.; Gladman, J.T.; Koenig, J.I.; Moy, C.S.; Pahigiannis, K.; Waddy, S.P.; Koroshetz, W. The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline. Cell Mol. Neurobiol. 2016, 36, 281–288.
  4. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat. Rev. Neurosci. 2011, 12, 723–738.
  5. Rajani, R.M.; Quick, S.; Ruigrok, S.R.; Graham, D.; Harris, S.E.; Verhaaren, B.F.J.; Fornage, M.; Seshadri, S.; Atanur, S.S.; Dominiczak, A.F.; et al. Reversal of endothelial dysfunction reduces white matter vulnerability in cerebral small vessel disease in rats. Sci. Transl. Med. 2018, 10, eaam9507.
  6. Pantoni, L. Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010, 9, 689–701.
  7. Bai, T.; Yu, S.; Feng, J. Advances in the Role of Endothelial Cells in Cerebral Small Vessel Disease. Front. Neurol. 2022, 13, 861714.
  8. Rouhl, R.P.; van Oostenbrugge, R.J.; Damoiseaux, J.G.; Debrus-Palmans, L.L.; Theunissen, R.O.; Knottnerus, I.L.; Staals, J.E.; Delanghe, J.R.; Tervaert, J.W.; Lodder, J. Haptoglobin phenotype may alter endothelial progenitor cell cluster formation in cerebral small vessel disease. Curr. Neurovasc. Res. 2009, 6, 32–41.
  9. Rouhl, R.P.; Mertens, A.E.; van Oostenbrugge, R.J.; Damoiseaux, J.G.; Debrus-Palmans, L.L.; Henskens, L.H.; Kroon, A.A.; de Leeuw, P.W.; Lodder, J.; Tervaert, J.W. Angiogenic T-cells and putative endothelial progenitor cells in hypertension-related cerebral small vessel disease. Stroke 2012, 43, 256–258.
  10. Kapoor, A.; Gaubert, A.; Marshall, A.; Meier, I.B.; Yew, B.; Ho, J.K.; Blanken, A.E.; Dutt, S.; Sible, I.J.; Li, Y.; et al. Increased Levels of Circulating Angiogenic Cells and Signaling Proteins in Older Adults With Cerebral Small Vessel Disease. Front. Aging Neurosci. 2021, 13, 711784.
  11. Huang, Z.X.; Fang, J.; Zhou, C.H.; Zeng, J.; Yang, D.; Liu, Z. CD34+ cells and endothelial progenitor cell subpopulations are associated with cerebral small vessel disease burden. Biomark Med. 2021, 15, 191–200.
  12. Heller, L.; Thinard, R.; Chevalier, M.; Arpag, S.; Jing, Y.; Greferath, R.; Heller, R.; Nicolau, C. Secretion of proteins and antibody fragments from transiently transfected endothelial progenitor cells. J. Cell Mol. Med. 2020, 24, 8772–8778.
  13. Sargento-Freitas, J.; Aday, S.; Nunes, C.; Cordeiro, M.; Gouveia, A.; Silva, F.; Machado, C.; Rodrigues, B.; Santo, G.C.; Ferreira, C.; et al. Endothelial Progenitor Cells influence acute and subacute stroke hemodynamics. J. Neurol. Sci. 2018, 385, 119–125.
  14. Hu, X.; De Silva, T.M.; Chen, J.; Faraci, F.M. Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke. Circ. Res. 2017, 120, 449–471.
  15. Blum, A.; Vaispapir, V.; Keinan-Boker, L.; Soboh, S.; Yehuda, H.; Tamir, S. Endothelial dysfunction and procoagulant activity in acute ischemic stroke. J. Vasc. Interv. Neurol. 2012, 5, 33–39.
  16. Schmidt-Lucke, C.; Rössig, L.; Fichtlscherer, S.; Vasa, M.; Britten, M.; Kämper, U.; Dimmeler, S.; Zeiher, A.M. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111, 2981–2987.
  17. Umemura, T.; Soga, J.; Hidaka, T.; Takemoto, H.; Nakamura, S.; Jitsuiki, D.; Nishioka, K.; Goto, C.; Teragawa, H.; Yoshizumi, M.; et al. Aging and hypertension are independent risk factors for reduced number of circulating endothelial progenitor cells. Am. J. Hypertens. 2008, 21, 1203–1209.
  18. Golab-Janowska, M.; Paczkowska, E.; Machalinski, B.; Kotlega, D.; Meller, A.; Safranow, K.; Wankowicz, P.; Nowacki, P. Elevated Inflammatory Parameter Levels Negatively Impact Populations of Circulating Stem Cells (CD133+), Early Endothelial Progenitor Cells (CD133+/VEGFR2+), and Fibroblast Growth Factor in Stroke Patients. Curr. Neurovasc. Res. 2019, 16, 19–26.
  19. Zhou, W.J.; Zhu, D.L.; Yang, G.Y.; Zhang, Y.; Wang, H.Y.; Ji, K.D.; Lu, Y.M.; Gao, P.J. Circulating endothelial progenitor cells in Chinese patients with acute stroke. Hypertens. Res. 2009, 32, 306–310.
  20. Bogoslovsky, T.; Spatz, M.; Chaudhry, A.; Maric, D.; Luby, M.; Frank, J.; Warach, S. NINDS Natural History of Stroke Investigators. Stromal-derived factor-1 correlates with circulating endothelial progenitor cells and with acute lesion volume in stroke patients. Stroke 2011, 42, 618–625.
  21. Kukumberg, M.; Zaw, A.M.; Wong, D.H.C.; Toh, C.M.; Chan, B.P.L.; Seet, R.C.S.; Wong, P.T.H.; Yim, E.K.F. Characterization and Functional Assessment of Endothelial Progenitor Cells in Ischemic Stroke Patients. Stem Cell Rev. Rep. 2021, 17, 952–967.
  22. Loiola, R.A.; García-Gabilondo, M.; Grayston, A.; Bugno, P.; Kowalska, A.; Duban-Deweer, S.; Rizzi, E.; Hachani, J.; Sano, Y.; Shimizu, F.; et al. Secretome of endothelial progenitor cells from stroke patients promotes endothelial barrier tightness and protects against hypoxia-induced vascular leakage. Stem Cell Res. Ther. 2021, 12, 552.
  23. Bogoslovsky, T.; Chaudhry, A.; Latour, L.; Maric, D.; Luby, M.; Spatz, M.; Frank, J.; Warach, S. Endothelial progenitor cells correlate with lesion volume and growth in acute stroke. Neurology 2010, 75, 2059–2062.
  24. Sobrino, T.; Hurtado, O.; Moro, M.A.; Rodríguez-Yáñez, M.; Castellanos, M.; Brea, D.; Moldes, O.; Blanco, M.; Arenillas, J.F.; Leira, R.; et al. The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke 2007, 38, 2759–2764.
  25. Yip, H.K.; Chang, L.T.; Chang, W.N.; Lu, C.H.; Liou, C.W.; Lan, M.Y.; Liu, J.S.; Youssef, A.A.; Chang, H.W. Level and value of circulating endothelial progenitor cells in patients after acute ischemic stroke. Stroke 2008, 39, 69–74.
  26. Rakkar, K.; Othman, O.; Sprigg, N.; Bath, P.; Bayraktutan, U. Endothelial progenitor cells, potential biomarkers for diagnosis and prognosis of ischemic stroke: Protocol for an observational case-control study. Neural. Regen. Res. 2020, 15, 1300–1307.
  27. Abdulkadir, R.R.; Alwjwaj, M.; Othman, O.A.; Rakkar, K.; Bayraktutan, U. Outgrowth endothelial cells form a functional cerebral barrier and restore its integrity after damage. Neural. Regen. Res. 2020, 15, 1071–1078.
  28. Kadir, R.R.A.; Alwjwaj, M.; Rakkar, K.; Othman, O.A.; Sprigg, N.; Bath, P.M.; Bayraktutan, U. Outgrowth Endothelial Cell Conditioned Medium Negates TNF-α-Evoked Cerebral Barrier Damage: A Reverse Translational Research to Explore Mechanisms. Stem Cell Rev. Rep. 2022. ahead of print.
  29. Paolucci, M.; Altamura, C.; Vernieri, F. The Role of Endothelial Dysfunction in the Pathophysiology and Cerebrovascular Effects of Migraine: A Narrative Review. J. Clin. Neurol. 2021, 17, 164–175.
  30. Hu, X.; Zhou, Y.; Zhao, H.; Peng, C. Migraine and the risk of stroke: An updated meta-analysis of prospective cohort studies. Neurol. Sci. 2017, 38, 33–40.
  31. Lee, S.T.; Chu, K.; Jung, K.H.; Kim, D.H.; Kim, E.H.; Choe, V.N.; Kim, J.H.; Im, W.S.; Kang, L.; Park, J.E.; et al. Decreased number and function of endothelial progenitor cells in patients with migraine. Neurology 2008, 70, 1510–1517.
  32. Rodríguez-Osorio, X.; Sobrino, T.; Brea, D.; Martínez, F.; Castillo, J.; Leira, R. Endothelial progenitor cells: A new key for endothelial dysfunction in migraine. Neurology 2012, 79, 474–479.
  33. Liman, T.G.; Neeb, L.; Rosinski, J.; Reuter, U.; Endres, M. Stromal Cell-Derived Factor-1 Alpha Is Decreased in Women with Migraine with Aura. Headache 2016, 56, 1274–1279.
  34. Leite, A.R.; Borges-Canha, M.; Cardoso, R.; Neves, J.S.; Castro-Ferreira, R.; Leite-Moreira, A. Novel Biomarkers for Evaluation of Endothelial Dysfunction. Angiology 2020, 71, 397–410.
  35. Liman, T.G.; Bachelier-Walenta, K.; Neeb, L.; Rosinski, J.; Reuter, U.; Böhm, M.; Endres, M. Circulating endothelial microparticles in female migraineurs with aura. Cephalalgia 2015, 35, 88–94.
  36. Oterino, A.; Toriello, M.; Palacio, E.; Quintanilla, V.G.; Ruiz-Lavilla, N.; Montes, S.; Vega, M.S.; Martinez-Nieto, R.; Castillo, J.; Pascual, J. Analysis of endothelial precursor cells in chronic migraine: A case-control study. Cephalalgia 2013, 33, 236–244.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback